Managing statin-induced muscle toxicity in a lipid clinic

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 3, 2011, Pages 336-341

  Blaier, O ^a   Lishner, M ^a,b   Elis, A ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

creatine kinase; LDL C; lipid clinic; muscle toxicity; statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG POTENCY; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; INJURY SEVERITY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCLE INJURY; MUSCLE TOXICITY; MYALGIA; MYOPATHY; MYOSITIS; PATIENT REFERRAL; PROPHYLAXIS; RHABDOMYOLYSIS; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL, LDL; CORONARY DISEASE; CREATINE KINASE; DRUG MONITORING; EARLY DIAGNOSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; ISRAEL; MALE; MEDICAL RECORDS; MIDDLE AGED; MUSCLES; MUSCULAR DISEASES; MYOSITIS; OUTPATIENT CLINICS, HOSPITAL; PAIN MEASUREMENT; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; RHABDOMYOLYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 79955752610     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01254.x     Document Type: Article

References (21)

1. Grundy SM, Cleeman JI, Merz CN, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 110, 227-239. (Pubitemid 38924592)
2. Jamal SM, Eisenberg MJ, Christopoulos S, (2004) Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. American Heart Journal, 147, 956-965. (Pubitemid 38880948)
3. Abu RV, Yasmin SH, Peter HJ, (2005) Safety of statins: effect on muscle and liver. Cleveland Clinic Journal of Medicine, 72, 990-1001.
4. Bellosta S, Paoletti R, Corsini A, (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation, 109 (Suppl. 1), III50-III57. (Pubitemid 38786444)
5. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation, 106, 1024-1028. (Pubitemid 34925341)
6. Thompson PD, Clarkson P, Karas RH, (2003) Statin-associated myopathy. Journal of the American Medical Association, 289, 1681-1690. (Pubitemid 37430274)
7. Thompson PD, Clarkson PM, Rosenson RS, (2006) An assessment of statin safety by muscle experts. American Journal of Cardiology, 97 (Suppl. 8A), 69C-76C.
8. Omar MA, Wilson JP, Cox TS, (2001) Rhabdomyolysis and HMG-CoA reductase inhibitors. Annals of Pharmacotherapy, 35, 1096-1107. (Pubitemid 32880030)
9. Bays H, (2006) Statin safety: an overview and assessment of the data-2005. The American Journal of Cardiology, 97 (Suppl. 8A), 6C-26C.
10. Hamilton-Craig I, (2001) Statin-associated myopathy. The Medical Journal of Australia, 175, 486-489. (Pubitemid 33039862)
11. Rosenson RS, (2004) Current overview of statin-induced myopathy. American Journal of Medicine, 116, 408-416. (Pubitemid 38299486)
12. Ballantyne CM, Corsini A, Davidson MH, et al. (2003) Risk for myopathy with statin therapy in high-risk patients. Archives of Internal Medicine, 163, 553-564. (Pubitemid 36314342)
13. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH, (2001) Lipid-lowering drugs and risk for myopathy: a population-based follow-up study. Epidemiology, 12, 565-569. (Pubitemid 32761999)
14. Brewer HB Jr, (2003) Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. American Journal of Cardiology, 92, 23K-29K.
15. The 4S study group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
16. Dujovne CA, Chremos AN, Pool JL, et al. (1991) Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. American Journal of Medicine, 91, 25S-30S.
17. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360, 7-22.
18. Downs JR, Clearfield M, Weis S, et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study). Journal of the American Medical Association, 279, 1615-1622. (Pubitemid 28248586)
19. Downs JR, Clearfield M, Tyroler HA, et al. (2001) Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. American Journal of Cardiology, 87, 1074-1079. (Pubitemid 32710322)
20. Stein EA, Ballantyne CM, Winder E, et al. (2008) Efficacy and tolerability of fluvastatin XL 80 mg, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. American Journal of Cardiology, 101, 490-496. (Pubitemid 351199443)
21. Hansen KE, Hildebrand JP, Ferguson EE, Stein JN, (2005) Outcomes in 45 patients with statin-associated myopathy. Archives of Internal Medicine, 165, 2671-2676. (Pubitemid 41785067)